Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

OBJECTIVE: We describe a phase II clinical trial of the combination of ribociclib and letrozole for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and endometrial cancer (EC). The primary endpoint was the proportion of patients alive, progression-free survival (PFS), and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Colon-Otero, Gerardo, Zanfagnin, Valentina, Hou, Xiaonan, Foster, Nathan R, Asmus, Erik J, Wahner Hendrickson, Andrea, Jatoi, Aminah, Block, Matthew S, Langstraat, Carrie L, Glaser, Gretchen E, Dinh, Tri A, Robertson, Matthew W, Camoriano, John K, Butler, Kristina A, Copland, John A, Weroha, S John
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592247/
https://ncbi.nlm.nih.gov/pubmed/33109627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000926
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados